AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.
Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.
The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.
Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.
As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities.
FEATURED STORIES
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
High-quality cytokines for organoid growth, differentiation, and expansion.
At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.
While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism.
After years of quiet maturation, new approach methodologies and emerging clinical success for cell therapies are fueling parallel momentum for induced pluripotent stem cells.
FROM BIOSPACE INSIGHTS
CDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration built on shared risk, regulatory fluency and technical insight. As rising compliance pressure and geopolitical volatility reshape manufacturing, partners like Rose BioSolutions argue that true value now comes from challenging assumptions, anticipating hurdles and protecting programs before problems surface.
LATEST PODCASTS
In this episode of Denatured, presented by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we explore how biopharma’s real bottleneck isn’t too little data—it’s too little confidence in the decisions that drive development, manufacturing and commercialization.
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Subscribe to GenePool
Subscribe to BioSpace’s flagship publication including top headlines, special editions and life sciences’ most important breaking news
SPECIAL EDITIONS
As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
BioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.
Job postings increase and competition dips, according to BioSpace data.
DEALS
-
Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale. -
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy. -
A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them. -
The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors. -
Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.
WEIGHT LOSS
-
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country. -
Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments. -
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top. -
For the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide. -
Viking Therapeutics rode strong obesity data before a major capital raise, while Longeveron’s mid-stage setback prompted questions about its future.
POLICY
-
Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H initiatives to modernize clinical trial design, site activation, consent and patient data collection. -
As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regulation could help the U.S. maintain its edge. -
Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites. -
CSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor. It continues to be sold on the U.S. market by Amgen despite concerns raised by the FDA. -
Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program, representing some 89% of the branded drug market.
Based on typical fourth quarter hiring activity, biopharma job seekers should apply for open roles sooner than later. Recruiting and career coaching experts offer advice on timing, networking, interviewing and casting a wider net than usual during Q4.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
A career setback can teach you something useful—or teach you the wrong lesson. Executive coach Angela Justice explains how one difficult experience can quietly shape the choices that follow.
With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the qualifications, technical skills and mindset needed to land these coveted positions.
Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the funding events, milestones and company indicators most likely to lead to new jobs.
An executive who is rarely short on ideas needs someone to pull their big ideas through to implementation. Kaye/Bassman’s Michael Pietrack explains why this person, who he calls the implementer, may be the most important hire in the building.
HOTBEDS
REPORTS
This guide explores the evolving role of podcasts, webinars, and thought leadership programs in biopharma and provides practical recommendations for public relations agencies, corporate communications teams, and commercial marketers looking to elevate their visibility and influence.
Gain the latest insights into the biopharma hiring landscape with BioSpace’s Biopharma Job Market Report Q2 2026. Explore the trends shaping talent acquisition, from rising job postings and sustained R&D hiring to the market activity signaling stronger hiring demand ahead.
Opportunities increased by the end of the first quarter, according to BioSpace data.
CANCER
-
Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.” -
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out. -
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now “less likely.” -
Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner. -
The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
NEUROSCIENCE
-
Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel. -
While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting. -
After one patient death prompted an FDA hold this spring, Newron Pharmaceuticals has now shared that a total of four fatalities have been recorded among participants receiving its schizophrenia candidate. A fifth death was recorded among those taking the placebo. -
The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness. -
After a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.
CELL AND GENE THERAPY
-
Leveraging recently proposed regulatory flexibilities, the gene-editing sector is working to cut R&D costs and unlock indications that were previously economically unviable, according to a new playbook published by the Alliance for Regenerative Medicine. -
Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer. -
Not a month after reports of three deaths in autoimmune trials for Novartis’ CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease. -
Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk. -
Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, joins a wave of rejected or discouraged therapies on which the FDA has reversed previous guidance after the exit of former Commissioner Marty Makary.
